July 12, 2025

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street, Fort, Mumbai – 400 001

Ref: Scrip Code: 532296

To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Name: GLENMARK

Re: *Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations).*

Dear Sir,

Sub: Communication from U.S. FDA regarding the Company's Indore, Madhya Pradesh (India) facility

We wish to inform you that the Company has received a warning letter from the U.S. FDA for the Company's Indore, Madhya Pradesh (India) facility. The U.S. FDA had inspected the Glenmark's Indore site from 03 February 2025 to 14 February 2025.

The Company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility.

We are committed to addressing the concerns raised by the U.S. FDA and will work with the U.S. FDA to resolve these issues at the earliest. There was no observation related to data integrity reported. We uphold quality and compliance issues with utmost importance and remain committed to be compliant with CGMP quality standards across all our facilities.

This intimation is further to our communication dated May 9, 2025, about Indore facility receiving OAI status by U.S. FDA.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Harish Kuber

Digitally signed by Harish Kuber
Date: 2025.07.12 21:16:05 +05'30'

Harish Kuber
Company Secretary & Compliance Officer